Report overview
In cancers, where mutations have led to the loss of function of one gene, using a drug molecule that specifically targets the corresponding gene of the synlet pair has been demonstrated to be a viable and effective therapeutic regimen. Recent advances in biomarker research, including the development of companion diagnostics, in combination with modern molecular screening platforms, which include clustered regularly interspaced short palindromic repeats (CRISPR)- and RNA interference (RNAi)-based screening techniques, have led to the identification of a number of synthetically lethal gene pairs.
This report aims to provide a comprehensive presentation of the global market for Synthetic Lethality-based Drugs and Targets, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Synthetic Lethality-based Drugs and Targets. This report contains market size and forecasts of Synthetic Lethality-based Drugs and Targets in global, including the following market information:
Global Synthetic Lethality-based Drugs and Targets Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Synthetic Lethality-based Drugs and Targets market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Monotherapy Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Synthetic Lethality-based Drugs and Targets include AbbVie, AstraZeneca, BeiGene, Clovis Oncology, GlaxoSmithKline, Pfizer, AtlasMedx, Chordia Therapeutics and IDEAYA Biosciences, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Synthetic Lethality-based Drugs and Targets companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Synthetic Lethality-based Drugs and Targets Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Synthetic Lethality-based Drugs and Targets Market Segment Percentages, by Type, 2022 (%)
Monotherapy
Combination Therapy
Global Synthetic Lethality-based Drugs and Targets Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Synthetic Lethality-based Drugs and Targets Market Segment Percentages, by Application, 2022 (%)
Medical Research Institution
Hospital and Clinic
Other
Global Synthetic Lethality-based Drugs and Targets Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Synthetic Lethality-based Drugs and Targets Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Synthetic Lethality-based Drugs and Targets revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Synthetic Lethality-based Drugs and Targets revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
AstraZeneca
BeiGene
Clovis Oncology
GlaxoSmithKline
Pfizer
AtlasMedx
Chordia Therapeutics
IDEAYA Biosciences
Mission Therapeutics
Repare Therapeutics
Sierra Oncology
SyntheX Labs
Outline of Major Chapters:
Chapter 1: Introduces the definition of Synthetic Lethality-based Drugs and Targets, market overview.
Chapter 2: Global Synthetic Lethality-based Drugs and Targets market size in revenue.
Chapter 3: Detailed analysis of Synthetic Lethality-based Drugs and Targets company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Synthetic Lethality-based Drugs and Targets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
